Breakthrough in Cancer Therapy: Nanoplatforms for Targeted Treatment

Researchers at Xuzhou Medical University, in collaboration with other institutions, have developed a novel nanoplatform for cancer therapy, combining magnetic resonance imaging (MRI) guidance with cascade catalyzed therapy and low-temperature photothermal therapy. The platform, composed of a S, Pd modified hollow CoNiMnFe Prussian blue analogue nanocomposite (Pd-S-CNMF), has been shown to enhance the efficiency of cancer treatment by remodeling the tumor microenvironment (TME) and generating highly toxic reactive oxygen species (ROS) and hyperthermia.

Key Takeaways:

• The researchers have designed a multifunctional nanoplatform, Pd-S-CNMF, which combines MRI guidance with cascade catalyzed therapy and low-temperature photothermal therapy for cancer treatment.
• The platform has been shown to possess superior magnetic TME sensitive MRI performance, enabling accurate tumor targeting.
• The co-modification of S and Pd on CNMF enhances the platform's responsive feature to acidic environments, enabling multiple enzyme mimicking activities and enhanced near-infrared (NIR) light absorption.
• Tanespimycin, a HSP 90 protein inhibitor, was loaded onto Pd-S-CNMF (17Pd-S-CNMF) to inhibit the level of HSP 90 protein, thereby increasing the outcome of subsequent photothermal therapy.
• The 17Pd-S-CNMF showed superior magnetic MRI performance and was effective in inhibiting the growth of prostate cancer in vitro and vivo.
• This research provides a paradigm for constructing efficient nanocomposites as nanoplatforms for cancer diagnosis and treatment.

Statistics:

• The platform, Pd-S-CNMF, has been shown to have superior magnetic TME sensitive MRI performance, surpassing that of pristine CNMF and S-doped CNMF.
• The study reported that the platform generated sustained ROS production and hyperthermia, enhancing the efficacy of chemodynamic therapy (CDT) and photothermal therapy (PTT).
• The loading of tanespimycin onto Pd-S-CNMF significantly inhibited the growth of prostate cancer in vitro and vivo, indicating its potential as a targeted cancer therapy.

Sources:

• Pd, S co-modified Prussian blue analogues nanocomposites for MRI guided combined mitochondria-targeting cancer therapy with tumor microenvironment remodeling, multienzyme-like catalysis and mild photothermal therapeutic effect (Colloids and Surfaces B-biointerfaces, 2025;254:114834)
• VerticalNews. "New research on Cancer from Xuzhou Medical University provides new data" (Nanotechnology Weekly, 2025; p 544)